FOLD Q1 2025 Earnings — Amicus Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FOLDAmicus Therapeutics, Inc.

$5B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$125M+13.4% YoY

Gross Profit

$114M90.7% margin

Operating Income

-$8M-6.3% margin

Net Income

-$22M-17.3% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

-16.3%

Cash Flow

Operating Cash Flow

$8M

Free Cash Flow

$8M

Stock-Based Comp.

$25M

Balance Sheet

Total Assets

$790M

Total Liabilities

$596M

Stockholders' Equity

$194M

Cash & Equivalents

$182M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$125M	$110M	+13.4%
Gross Profit	$114M	$97M	+17.3%
Operating Income	-$8M	-$28M	+71.3%
Net Income	-$22M	-$48M	+55.2%

Geographic Segments

Non-US

$64M61%

UNITED STATES

$40M39%